חזרה לתוצאות החיפוש

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Higher-risk Myelodysplastic Syndromes

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • UCLA Ronald Reagan Medical Center, Los Angeles, California, United States

  • Rocky Mountain Cancer Centers, Aurora, Colorado, United States

  • Yale Cancer Center, New Haven, Connecticut, United States

  • Mid Florida Hematology and Oncology Center, Orange City, Florida, United States

  • American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda), Bethesda, Maryland, United States

  • Maryland Oncology-Columbia, Columbia, Maryland, United States

  • Washington University School of Medicine in St. Louis, St Louis, Missouri, United States

  • Montefiore Einstein Comprehensive Cancer Center, The Bronx, New York, United States

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

  • Gabrail Cancer Center, Canton, Ohio, United States

  • Ohio State University, Columbus, Ohio, United States

  • Oncology Associates of Oregon, Eugene, Oregon, United States

    Contact: Study coordinator (Luke Fletcher) · luke.fletcher@usoncology.com

  • MUSC Hollings Cancer Center, Charleston, South Carolina, United States

  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Yazan Madanat) · yazan.madanat@utsouthwestern.edu

  • Institute of hematolongy&blood diseases hospital, chinese academy of medical sciences&peking union medical college, Tianjin, China

    Contact: Study coordinator (Zhijian Xiao)
צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)